In vivo study on the effects of α1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 256-261

  Noguchi, Yukiko ^a   Ohtake, Akiyoshi ^a   Suzuki, Masanori ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

1 adrenoceptor antagonist; Intraluminal pressure of vas deferens; Intraurethral pressure

Indexed keywords

ALFUZOSIN; NAFTOPIDIL; PHENYLEPHRINE; PRAZOSIN; SILODOSIN; TAMSULOSIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG DOSE INCREASE; EJACULATION DISORDER; IN VIVO STUDY; INTESTINE PRESSURE; MALE; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; URETHRA; URETHRA PRESSURE; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EJACULATION; INDOLES; MALE; NAPHTHALENES; PHENYLEPHRINE; PIPERAZINES; PRAZOSIN; PRESSURE; PROSTATE; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; URETHRA; VAS DEFERENS;

EID: 37649019743     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.003     Document Type: Article

References (37)

1. Banks F.C., Knight G.E., Calvert R.C., Thompson C.S., Morgan R.J., and Burnstock G. The purinergic component of human vas deferens contraction. Fertil. Steril. 85 (2006) 932-939
2. 1B-adrenoceptor mediating contraction of the rat spleen. Br. J. Pharmacol. 115 (1995) 467-475
3. Caine M., Pfau A., and Perlberg S. The use of alpha-adrenergic blockers in benign prostatic hyperplasia. Br. J. Urol. 48 (1976) 255-263
4. Debruyne F.M. Alpha blockers: are all created equal?. Urology 56 (2000) 20-22
5. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. 288 (1995) 201-207
6. Furuya R., Hisasue S., Ogura H., Furuya S., Masumori N., Itoh N., and Tsukamoto T. Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin. (Japanese). Hinyokika Kiyo-Acta Urologica Japonica 51 (2005) 763-766
7. 1-adrenoceptor antagonist with uroselective properties. J. Pharmacol. Exp. Ther. 300 (2002) 478-486
8. Hieble J.P., Caine M., and Zalaznik E. In vitro characterization of the a-adrenoceptors in human prostate. Eur. J. Pharmacol. 107 (1985) 111-117
9. Hieble J.P., Bylund D.B., Clarke D.E., Eikenburg D.C., Langer S.Z., Lefkowitz R.J., Minneman K.P., and Ruffolo R.R. International Union of Pharmacology X. Recommendation for nomenclature of α1-adrenoceptors: consensus update. Pharmacol. Rev. 47 (1995) 267-270
10. Hisasue S., Furuya R., Itoh N., Kobayashi K., Furuya S., and Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 13 (2006) 1311-1316
11. Hofner K., Claes H., De Reijeke T.M., Folkestad B., and Speakman M.J. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 36 (1999) 335-341
12. 1A-adrenoceptor- selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 98 (2006) 1019-1024
13. Kedia K., and Markland C. The effect of pharmacological agents on ejaculation. J. Urol. 114 (1975) 569-573
14. Kedia K.R., and Persky L. Effect of phenoxybenzamine (dibenzyline) on sexual function in man. Urology 18 (1981) 620-621
15. Kihara K., Sato K., Ando M., Sato T., and Oshima H. A mechanism of retrograde ejaculation after bilateral hypogastric nerve transections in the dog. J. Urol. 148 (1992) 1307-1309
16. Kim S.W., Lee S.H., and Paick J.S. In vivo rat model to measure hypogastric nerve stimulation-induced seminal vesicle and vasal pressure responses simultaneously. Int. J. Impot. Res. 16 (2004) 427-432
17. Kojima Y., Sasaki S., Shinoura H., Hayashi Y., Tsujimoto G., and Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 66 (2006) 761-767
18. Kondo S., Tashima Y., and Morita T. Segmental differences in the density of autonomic receptors in dog vas deferens. Urol. Int. 53 (1994) 62-67
19. 1-adrenoceptor antagonist in the lower urinary tract. Br. J. Pharmacol. 109 (1993) 1282-1289
20. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51 (1998) 892-900
21. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G., Haakenson C., Machi M., Narayan P., and Padley R.J. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 335 (1996) 533-539
22. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 352 (1995) 1-10
23. 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br. J. Pharmacol. 122 (1997) 1009-1014
24. 1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Br. J. Pharmacol. 127 (1999) 19-26
25. Nakanishi H., Ohkubo S., Ono T., Matsuoka I., and Nakahata N. A comparative study on contractile responses of rabbit and guinea pig vasa deferentia to electrical field stimulation. Fukushima J. Med. Sci. 50 (2004) 55-64
26. Narayan P., and Tewari A. Overview of α-blocker therapy for benign prostatic hyperplasia. Urology 51 (1998) 38-45
27. 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. Pharmacol. 119 (1996) 797-803
28. 1-adrenoceptors. Eur. J. Pharmacol. 291 (1995) 327-334
29. Ohtake A., Sato S., Saitoh C., Yuyama H., Sasamata M., and Miyata K. Effects of tamsulosin on hypogastric nerve stimulation-induced intraurethral pressure elevation in male and female dogs under anesthesia. Eur. J. Pharmacol. 497 (2004) 327-334
30. 1-Adrenoceptors are required for normal male sexual function. Br. J. Pharmacol. 152 (2007) 332-340
31. Sato S., Ohtake A., Hatanaka T., Suzuki M., Matsushima H., Sasamata M., and Miyata K. Relationship between the functional effect of tamsulosin and its concentration in lower urinary tract tissues in dogs. Biol. Pharm. Bull. 30 (2007) 481-486
32. Shima S. Characterization of adrenergic receptors in membranes from the rat seminal vesicle. Jpn. J. Pharmacol. 61 (1993) 87-92
33. Solomon H.M., Wier P.J., Ippolito D.L., and Toscano T.V. Effect of prazosin on sperm transport in male rats. Reprod. Toxicol. 11 (1997) 627-631
34. Takei R., Ikegaki I., Shibata K., Tsujimoto G., and Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn. J. Pharmacol. 79 (1999) 447-454
35. 1-adrenoceptor antagonist. Yakugaku Zasshi 115 (1995) 773-789
36. Tambaro S., Ruiu S., Dessi C., Mongeau R., Marchese G., and Pani L. Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays. J. Pharmacol. Exp. Ther. 312 (2005) 710-717
37. Van Kerrebroeck P., Jardin A., Van Cangh P., and Laval K.U. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol. 41 (2002) 54-61